

Comparative study of the effects of Nimesulide, Celecoxib and Indomethacin on hepatic and gastric tissues in rats

Thesis

Submitted in Partial Fulfillment of M.Sc. Degree in Pharmacology

By:

Marie Nabil Samwel Gendy

M.B., B.Ch.

Demonstrator of Pharmacology

Faculty of Medicine, Cairo University

Supervisors:

Prof. Dr. Mona Osman Abdel Halim

Professor of Pharmacology

Faculty of Medicine, Cairo University

Assis. Prof. Dr. Amira Ahmed Hassouna

Assistant Professor of Biochemistry

Faculty of Medicine, Cairo University

Dr. Marian Youssry Wissa

Lecturer of Pharmacology

Faculty of Medicine, Cairo University

Faculty of Medicine

Cairo University

2011

ACKNOWLEDGEMENT

First of all, I thank You and praise You, O God for Your mercy that endures forever. In all my ways I shall acknowledge The LORD, and He shall direct my paths.

I would like to express my deep gratitude, appreciation and sincere thanks to **Prof. Dr. Mona Osman Abdel Halim**, *Professor of Pharmacology, Faculty of Medicine, Cairo University*, for her support, meticulous supervision, great valuable remarks, encouragement and assistance until this work was fulfilled.

Deep thanks to **Assis. Prof. Dr. Amira Ahmed Hassouna**, *Assistant Professor of Biochemistry, Faculty of Medicine, Cairo University*, for her kind help, guidance and for her valuable assistance in completing this work.

I am very grateful to **Dr. Marian Youssry Wissa**, *lecturer of Pharmacology, Faculty of Medicine, Cairo University*, for her great help in every step and effective guidance throughout this study.

I would also like to express my special deep thanks and gratitude to **Prof. Dr. Bahaa Ehab Mounir**, *Professor of Pathology, Faculty of Medicine, Cairo University*, for his generous help in analysis of our pathological findings.

Finally, I would like to dedicate this work to my beloved husband for his great help and support during the preparation of this thesis, and for all my family members for their great encouragement, continuous support and sincere love throughout my life.

ABSTRACT

Nimesulide, a non-steroidal anti-inflammatory drug (NSAID) with preferential COX-2 inhibition, was found to be well-tolerated in patients as it causes less gastro-intestinal side effects compared with other non-selective NSAIDs. Its safety on the liver is controversial.

In the present study, three different NSAIDs were used: a non-selective drug (indomethacin), a partially selective one (nimesulide), and a selective COX-2 inhibitor (celecoxib). Albino rats were used and were divided into two main groups: group I: normal rats that were divided into 4 subgroups, and group II: thioacetamide induced hepatotoxicity group. Pyloric ligation was performed; gastric acidity and mean ulcer score were measured to assess the effect of different drugs on the gastric tissue. Liver function tests and histo-pathological examination of the stomach and the liver were performed.

Nimesulide showed good gastric tolerance. However, it elevated significantly most of the hepatic bio-chemical and histo-pathological parameters in comparison to other drugs in healthy and diseased liver. Celecoxib and indomethacin effects on liver were variable.

Keywords: Nimesulide; Celecoxib; Indomethacin; Thioacetamide; Hepatotoxicity; Gastric Acidity; Mean Ulcer Score; Pyloric Ligation.

CONTENTS

	Page
Acknowledgement	i
Abstract	ii
Table of Contents	iii
List of Abbreviations	iv
List of Tables	vi
List of Figures	viii
List of Photos	x
 Introduction	 1
 Review of Literature	 2
Celecoxib	11
Nimesulide	15
Indomethacin	20
Drug Induced Hepatotoxicity.....	23
 Aim of the work	 32
 Materials and Methods	 33
Materials	33
Methods	37
Statistical Analysis	45
 Results	 46
Results of Group I	46
Hepatic Pathological Changes in Group I	58
Mean Ulcer Score and Gastric Pathological Changes in Group I.	73
Results of Group II	78
Hepatic Pathological Changes in Group II	88
 Discussion	 103
 Summary and Conclusion.....	 116
 References	 120

LIST OF ABBREVIATIONS

ALT:	Alanine transferase
ALP:	Alkaline phosphatase
ANOVA:	Analysis of Variance
AST:	Aspartate transferase
ATP:	Adenosine triphosphate
bid:	Twice daily
CHUMP:	Committee for Medicinal Products for Human use
CNS:	Central nervous system
COX:	Cyclooxygenase enzyme
COXIBs:	Cyclooxygenase -2-selective inhibitors
CSF:	Cerebrospinal fluid
CV:	Cardio-vascular
CYP:	Cytochrome P
DILI:	Drug-induced liver injury
DMARD:	Disease modifying anti-rheumatic drug
DNPH:	Dinitrophenylhydrazine
ECL:	Enterochromaffin-like
EMA:	The European Medicines Agency
EU:	European Union
FDA:	Food and Drug Administration
FOI:	Freedom of Information
GI:	Gastro-intestinal
GOT:	Glutamic oxaloacetic transaminase
GPT:	Glutamic pyruvic transaminase
GSH:	Glutathione
H&E:	Hematoxylin and Eosin
HAI:	Histology activity index
IFN:	Interferon
IL:	Interleukin
iNOS:	Inducible nitric oxide synthase

I.P.:	Intraperitoneal
IU:	International Unit
KC:	Kupffer cells
LOX:	Leukotriene oxygenase enzyme
LSD:	Least significant difference
LTs:	Leukotrienes
NAPQI:	N-acetyl-p-benzoquinone imine
NASH:	Non alcoholic steatohepatitis
NK:	Natural killer
NKT:	Natural killer T cells
NO:	Nitric oxide
NSAIDs:	Non-steroidal anti-inflammatory drugs
P-C:	Portal to central
PGI ₂ :	Prostacyclin
PGHS:	Prostaglandin-H ₂ synthase
PGs:	Prostaglandins
pH:	Power of hydrogen
pK _a :	Acid dissociation constant
P-P:	Portal to portal
P.T.:	Portal tract
qid:	4 times daily
ROS:	Reactive oxygen species
SD:	Standard deviation
sPDA:	Symptomatic patent ductus arteriosis
TAA:	Thioacetamide
tds:	Three times daily
TNF- α :	Tumor necrosis factor-alpha
TXA ₂ :	Thromboxane A ₂
UK:	United Kingdom
ULN:	Upper limit of normal
US:	United States

LIST OF TABLES

	Page
Table 1. The pharmacokinetic properties of aspirin and some other non-steroidal anti-inflammatory drugs.	3
Table 2. Main mechanisms of hepatotoxicity.	27
Table 3. The mean serum AST, ALT and ALP levels in Group I.	48
Table 4. The mean serum total & direct bilirubin and albumin levels in Group I.	52
Table 5. The mean gastric acidity level in Group I.	56
Table 6. The extent of hepatic necrosis in Group I.	58
Table 7. The extent of hepatic cholestasis in Group I.	60
Table 8. The extent of hepatic steatosis in Group I.	62
Table 9. The extent of portal tract inflammation in Group I.	64
Table 10. The extent of lobular inflammation in Group I.	66
Table 11. The extent of hepatic fibrosis in Group I.	68
Table 12. The extent of sinusoidal and central vein congestion in Group I. ...	71
Table 13. Summary of the main hepatic pathological changes in Group I. ...	72
Table 14. The mean ulcer score and grades of erosions in Group I.	74
Table 15. The grades of gastritis in Group I.	76
Table 16. The mean serum AST, ALT and ALP levels in Group II.	81
Table 17. The mean serum total & direct bilirubin and albumin levels in Group II.	85
Table 18. The extent of hepatic necrosis in Group II.	88
Table 19. The extent of hepatic cholestasis in Group II.	90

Table 20. The extent of hepatic steatosis in Group II.	92
Table 21. The extent of portal tract inflammation in Group II.	94
Table 22. The extent of lobular inflammation in Group II.	96
Table 23. The extent of hepatic fibrosis in Group II.	98
Table 24. The extent of sinusoidal and central vein congestion in Group II. ...	100
Table 25. Summary of the main hepatic pathological changes in Group II. ...	102

LIST OF FIGURES

	Page
Figure 1. Origin and effects of prostaglandins.	5
Figure 2. Chemical structure of celecoxib.	11
Figure 3. PGs role in GIT.	13
Figure 4. Structure of nimesulide.	15
Figure 5. The structural formula of indomethacin, a methylated indole derivative.	20
Figure 6. Illustration of the proposed mechanisms of DILI.	30
Figure 7. The mean serum AST/GOT levels in Group I.	49
Figure 8. The mean serum ALT/GPT levels in Group I.	49
Figure 9. The mean serum ALP levels in Group I.	50
Figure 10. The mean serum total bilirubin levels in Group I.	53
Figure 11. The mean serum direct bilirubin levels in Group I.	53
Figure 12. The mean serum albumin levels in Group I.	54
Figure 13. The mean gastric acidity levels in Group I.	57
Figure 14. The extent of hepatic necrosis in Group I.	59
Figure 15. The extent of hepatic cholestasis in Group I.	61
Figure 16. The extent of hepatic steatosis in Group I.	63
Figure 17. The extent of portal tract inflammation in Group I.	65
Figure 18. The extent of lobular inflammation in Group I.	67
Figure 19. The extent of hepatic fibrosis in Group I.	69
Figure 20. The extent of sinusoidal and central vein congestion in Group I. ...	71

Figure 21. The mean ulcer score in Group I.	75
Figure 22. The grades of erosions in Group I.	75
Figure 23. The grades of gastritis in Group I.	76
Figure 24. The mean serum AST/GOT levels in Group II.	82
Figure 25. The mean serum ALT/GPT levels in Group II.	82
Figure 26. The mean serum ALP levels in Group II.	83
Figure 27. The mean serum total bilirubin levels in Group II.	86
Figure 28. The mean serum direct bilirubin levels in Group II.	87
Figure 29. The mean serum albumin levels in Group II.	87
Figure 30. The extent of hepatic necrosis in Group II.	89
Figure 31. The extent of hepatic cholestasis in Group II.	91
Figure 32. The extent of hepatic steatosis in Group II.	93
Figure 33. The extent of portal tract inflammation in Group II.	95
Figure 34. The extent of lobular inflammation in Group II.	97
Figure 35. The extent of hepatic fibrosis in Group II.	99
Figure 36. The extent of sinusoidal and central vein congestion in Group II. ...	101

LIST OF PHOTOS

	Page
Photo 1. Hepatic tissue in nimesulide Group I-B showing areas of necrosis and drop-outs. H&E stain (40×).	59
Photo 2. Hepatic tissue in nimesulide Group I-B showing areas of focal macrovesicular steatosis and lobular inflammation. H&E stain (100×).	63
Photo 3. Hepatic portal tract fibrosis and congestion as seen in Group I-B. Masson Trichrome stain (40×).	69
Photo 4. Hepatic tissue in nimesulide Group I-B showing areas of portal fibrosis, early fibrous expansion and congestion. Masson Trichrome stain (40×).	70
Photo 5. Unremarkable pathological changes in gastric tissues of: (A) nimesulide Group I-B, and (B) celecoxib Group I-C. H&E stain (40×).	77
Photo 6. Stomach ulcer Grade II in indometacin Group I-D. H&E stain (40×).	77
Photo 7. Hepatocellular necrosis, lobular inflammation and drop-outs in TAA control Group II-A. H&E stain (40×).	89
Photo 8. Hepatocellular necrosis, lobular inflammation and focal steatosis in Group II-B. H&E stain (40×).	93

INTRODUCTION

Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most widely used medications. The use of NSAIDs plays a fundamental role in controlling inflammation and pain relief (**Hawboldt, 2008**).

These drugs act on the cyclooxygenase enzyme (COX) that converts arachidonic acid into the endoperoxide precursors of prostaglandins, important mediators of inflammation. Cyclooxygenase has at least 2 isoforms: COX-1 and COX-2. COX-1 isoform tends to be homeostatic in function, while COX-2 is induced in inflammation and tends to facilitate the inflammatory response. Some of these drugs are non-selective, i.e. acting on both COX-1 and COX-2, such as aspirin, indomethacin, and diclofenac; while others are selective, i.e. act only on COX-2 inhibitors, such as celecoxib (**Furst et al., 2007**).

Nimesulide, a non-steroidal anti-inflammatory drug with preferential COX-2 inhibition (**Altinkaynak et al., 2003**), was found to be as effective as other NSAIDs in relieving pain. It has been shown that nimesulide is well-tolerated in patients who are intolerant to other NSAIDs (**Rainsford, 2006**) as it causes less gastro-intestinal side effects compared to other non-selective NSAIDs (**Borku et al., 2008**).

Its safety on the liver is controversial; some studies reported cases of nimesulide induced hepatotoxicity that could be fatal (**Tan et al., 2007**; **Page et al., 2009**), while others confirmed that liver insult induced by nimesulide is minimal (**Traversa et al., 2003**).

The European Medicines Agency (EMA) has completed a review of the liver related safety of nimesulide and has concluded that the benefits of medicines containing nimesulide still outweigh their risks. However, the agency advised to restrict the use of these medicines in children less than 12 years (**EMA, 2007**).

AIM OF THE WORK

The aim of this work is to compare the effects and safety of nimesulide, celecoxib, and indomethacin on the liver and gastric tissues in adult rats.

REVIEW OF LITERATURE

Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most frequently used classes of medicines in the world and account for nearly 5% of all prescribed medications (**Tomisato et al., 2004**).

It is expected that the use of NSAIDs will increase because the incidence of rheumatic diseases also is increasing. Their use is more frequent among women and increases with age, as does the incidence of rheumatic diseases. Indeed more than 90% of prescriptions for NSAIDs are made to patients aged more than 65 years (**Sostres et al., 2010**).

Regarding the pharmacokinetics of NSAIDs, they are weak acids with pKa less than 5. Most of them are rapidly absorbed following oral administration with peak plasma concentration reached within 2-3 hours. Moreover the rate and the extent of NSAIDs absorption are comparable for rectal and oral routes (**Buvanendran and Lipman, 2009**).

NSAIDs are extensively bound to plasma proteins, usually albumin. Their volume of distribution varies between 0.1 and 0.15 L/Kg. Conditions that alter plasma proteins concentration may result in an increase in the free drug fraction with potential of toxic effects. Most NSAIDs have the potential to displace other highly plasma proteins bound drugs (**Grosser, 2006**).

NSAIDs constitute a chemically heterogeneous group of drugs that differ in their therapeutic efficacy and toxicity. CYP2C8 (Cytochrome P) and CYP2C9 hepatic microsomal enzymes are the chief enzymes involved in the first steps of NSAIDs metabolism. However, the relative role of CYP2C enzymes in primary metabolism differs among different NSAIDs (**Agúndez et al., 2009**).

NSAIDs are mostly excreted by the kidney as phase II glucuronides and in a few cases as sulfate conjugates. In addition, small percentages of NSAIDs

are excreted unchanged in urine (Table1). If the drug is excreted unchanged and co-administered with agents that render the urine pH alkaline such as the antacids aluminum hydroxide and milk of magnesia, its rate of excretion is expected to increase (**Mehanna, 2003**).

Regarding the NSAIDs pharmacodynamics, they inhibit cyclooxygenase (COX), a key enzyme in the biosynthesis of prostaglandins from arachidonic acid. COX exists in at least two isoforms (**Kujubu et al., 1991; Hla and Neilson, 1992**). These two are COX-1 and COX-2. “Classical” NSAIDs are nonselective inhibitors of both isozymes (**Xie et al., 1992**).

Table 1. The pharmacokinetic properties of aspirin and some other non-steroidal anti-inflammatory drugs. *Quoted from (Furst et al., 2009. Katzung Basic & Clinical Pharmacology).*

Drug	Half-life (hours)	Urinary excretion of unchanged Drug	Recommended Anti-Inflammatory Dosage
Aspirin	0.25	< 2%	1200-1500 mg tds
Celecoxib	11	27%	100-200 mg bid
Diclofenac	1.1	< 1%	50 – 75 mg qid
Diflunisal	13	3 – 9%	500 mg bid
Etodolac	6.5	< 1%	200-300 mg qid
Fenoprofen	2.5	30%	600 mg qid
Flurbiprofen	3.8	< 1%	300 mg tds
Ibuprofen	2	< 1%	600 mg qid
Indomethacin	4 – 5	16%	50-70 mg tds
Ketoprofen	1.8	< 1%	70 mg tds
Ketorolac	4 – 10	58%	10 mg qid
Meloxicam	20	data not found	7.5-15 mg qd
Naproxen	14	< 1%	375 mg bid
Piroxicam	57	4-10%	20 mg qd
Sulindac	8	7%	200 mg bid